Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms XALIA
- Sponsors Bayer
- 06 Dec 2016 Results of a subgroup analysis in patients with cancer (n=587), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Subgroup analysis results published in a Janssen Pharmaceuticals media release.
- 06 Dec 2016 Subgroup analysis results from this trial presented at the 2016 American Society of Hematology (ASH) Annual Meeting, as per a Janssen Pharmaceuticals media release.